Quantisnow Logo
Dashboard

SEC Form SC 13G filed by Protara Therapeutics Inc.

$TARA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $TARA alert in real time by email
SC 13G 1 sc13g12927tara_12172024.htm THE SCHEDULE 13G

 UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No. )1

 

Protara Therapeutics, Inc.

 (Name of Issuer)

Common Stock, par value $0.001 per share

 (Title of Class of Securities)

74365U107

 (CUSIP Number)

December 10, 2024

 (Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

   ☐  Rule 13d-1(b)

   ☒  Rule 13d-1(c)

   ☐  Rule 13d-1(d)

 

 

 

1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

CUSIP No. 74365U107

 

  1   NAME OF REPORTING PERSON  
         
        Velan Capital Master Fund LP  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        CAYMAN ISLANDS  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         2,054,000*  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          2,054,000*  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        2,054,000*  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        5.9%*  
  12   TYPE OF REPORTING PERSON  
         
        PN  

  

* Includes 480,000 Shares (as defined below) issuable upon the exercise of certain warrants that are subject to a 9.99% beneficial ownership blocker provision (the “Warrants”).

2

CUSIP No. 74365U107

  1   NAME OF REPORTING PERSON  
         
        Velan Horizon Fund LP  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        DELAWARE  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         5,000  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          5,000  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        5,000  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        Less than 1%  
  12   TYPE OF REPORTING PERSON  
         
        PN  

  

3

CUSIP No. 74365U107

 

  1   NAME OF REPORTING PERSON  
         
        Velan Horizon GP LLC  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        DELAWARE  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         5,000  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          5,000  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        5,000  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        Less than 1%  
  12   TYPE OF REPORTING PERSON  
         
        OO  

  

4

CUSIP No. 74365U107

 

  1   NAME OF REPORTING PERSON  
         
        Velan Capital Holdings LLC  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        DELAWARE  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         2,054,000*  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          2,054,000*  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        2,054,000*  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        5.9%*  
  12   TYPE OF REPORTING PERSON  
         
        OO  

  

* Includes 480,000 Shares issuable upon the exercise of the Warrants.

5

CUSIP No. 74365U107

 

  1   NAME OF REPORTING PERSON  
         
        Velan Capital Investment Management LP  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        DELAWARE  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         2,059,000*  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          2,059,000*  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        2,059,000*  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        5.9%*  
  12   TYPE OF REPORTING PERSON  
         
        PN  

  

* Includes 480,000 Shares issuable upon the exercise of the Warrants.

6

CUSIP No. 74365U107

 

  1   NAME OF REPORTING PERSON  
         
        Velan Capital Management LLC  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        DELAWARE  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         2,059,000*  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          2,059,000*  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        2,059,000*  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        5.9%*  
  12   TYPE OF REPORTING PERSON  
         
        OO  

  

* Includes 480,000 Shares issuable upon the exercise of the Warrants.

7

CUSIP No. 74365U107

 

  1   NAME OF REPORTING PERSON  
         
        Adam Morgan  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        USA  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         2,059,000*  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          2,059,000*  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        2,059,000*  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        5.9%*  
  12   TYPE OF REPORTING PERSON  
         
        IN  

  

* Includes 480,000 Shares issuable upon the exercise of the Warrants.

8

CUSIP No. 74365U107

 

  1   NAME OF REPORTING PERSON  
         
        Balaji Venkataraman  
  2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
        (b) ☐
           
  3   SEC USE ONLY    
           
             
  4   CITIZENSHIP OR PLACE OF ORGANIZATION  
         
        USA  
NUMBER OF   5   SOLE VOTING POWER  
SHARES          
BENEFICIALLY         - 0 -  
OWNED BY   6   SHARED VOTING POWER  
EACH          
REPORTING         2,059,000*  
PERSON WITH   7   SOLE DISPOSITIVE POWER  
         
          - 0 -  
    8   SHARED DISPOSITIVE POWER  
           
          2,059,000*  
  9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
         
        2,059,000*  
  10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
       
           
  11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
        5.9%*  
  12   TYPE OF REPORTING PERSON  
         
        IN  

  

* Includes 480,000 Shares issuable upon the exercise of the Warrants.

9

CUSIP No. 74365U107

Item 1(a).Name of Issuer:

Protara Therapeutics, Inc., a Delaware corporation (the “Issuer”).

Item 1(b).Address of Issuer’s Principal Executive Offices:

345 Park Avenue South
Third Floor
New York, New York 10010

Item 2(a).Name of Person Filing:

This statement is filed by:

(i)Velan Capital Master Fund LP, an exempted limited partnership organized under the laws of the Cayman Islands (“Velan Master”), with respect to the Shares directly and beneficially owned by it;
(ii)Velan Horizon Fund LP, a Delaware limited partnership (“Velan Horizon”), with respect to the Shares directly and beneficially owned by it;
(iii)Velan Horizon GP LLC, a Delaware limited liability company (“Velan Horizon GP”), as the general partner of Velan Horizon;
(iv)Velan Capital Holdings LLC, a Delaware limited liability company (“Velan GP”), as the general partner of Velan Master;
(v)Velan Capital Investment Management LP, a Delaware limited partnership (“Velan Capital”), as the investment manager of each of Velan Master and Velan Horizon;
(vi)Velan Capital Management LLC, a Delaware limited liability company (“Velan IM GP”), as the general partner of Velan Capital;
(vii)Adam Morgan, as a Managing Member of each of Velan Horizon GP, Velan GP and Velan IM GP; and
(viii)Balaji Venkataraman, as a Managing Member of each of Velan Horizon GP, Velan GP and Velan IM GP.

Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

Item 2(b).Address of Principal Business Office or, if None, Residence:

The address of the principal office of Velan Master is 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands. The address of the principal office of each of Velan Horizon, Velan Horizon GP, Velan GP, Velan Capital, Velan IM GP and Messrs. Morgan and Venkataraman is 100 North Main Street, Suite 301, Alpharetta, Georgia 30009.

10

CUSIP No. 74365U107

Item 2(c).Citizenship:
(i)Velan Master – Cayman Islands
(ii)Velan Horizon – Delaware
(iii)Velan Horizon GP – Delaware
(iv)Velan GP – Delaware
(v)Velan Capital – Delaware
(vi)Velan IM GP – Delaware
(vii)Mr. Morgan – United States of America
(viii)Mr. Venkataraman – United States of America
Item 2(d).Title of Class of Securities:

Common Stock, par value $0.001 per share (the “Shares”).

Item 2(e).CUSIP Number:

74365U107

Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    /x/ Not applicable.
       
  (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
       
  (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
       
  (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
       
  (d) / / Investment company registered under Section 8 of the Investment Company Act.
       
  (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
       
  (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
       
  (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
       
  (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
       
  (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
       
  (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
       
  (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

 

11

CUSIP No. 74365U107

Item 4.Ownership.
(a)Amount beneficially owned:

As of the date hereof:

i.Velan Master directly beneficially owned 2,054,000 Shares, including 480,000 Shares issuable upon the exercise of the Warrants;
ii.Velan Horizon directly beneficially owned 5,000 Shares;
iii.Velan Horizon GP, as the general partner of Velan Horizon, may be deemed to beneficially own the 5,000 Shares beneficially owned directly by Velan Horizon;
iv.Velan GP, as the general partner of Velan Master, may be deemed to beneficially own the 2,054,000 Shares beneficially owned directly by Velan Master;
v.Velan Capital, as the investment manager of each of Velan Master and Velan Horizon, may be deemed to beneficially own the (i) 2,054,000 Shares beneficially owned directly by Velan Master and (ii) 5,000 Shares beneficially owned directly by Velan Horizon;
vi.Velan IM GP, as the general partner of Velan Capital, may be deemed to beneficially own the (i) 2,054,000 Shares beneficially owned directly by Velan Master and (ii) 5,000 Shares beneficially owned directly by Velan Horizon;
vii.Mr. Morgan, as a Managing Member of each of Velan Horizon GP, Velan GP and Velan IM GP, may be deemed to beneficially own the (i) 2,054,000 Shares beneficially owned directly by Velan Master and (ii) 5,000 Shares beneficially owned directly by Velan Horizon; and
viii.Mr. Venkataraman, as a Managing Member of each of Velan Horizon GP, Velan GP and Velan IM GP, may be deemed to beneficially own the (i) 2,054,000 Shares beneficially owned directly by Velan Master and (ii) 5,000 Shares beneficially owned directly by Velan Horizon.

The filing of this Schedule 13G shall not be deemed an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

(b)Percent of class:

The following percentages are based on 34,319,772 Shares outstanding as of December 11, 2024, which is the total number of Shares outstanding following the closing of the Issuer’s public offering, as disclosed in the Issuer’s Prospectus Supplement on Form 424B5 filed with the Securities and Exchange Commission on December 11, 2024 and the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 11, 2024, plus the Shares underlying the Warrants that may be exercised by the Reporting Persons, as applicable.

12

CUSIP No. 74365U107

As of the date hereof, (i) Velan Master beneficially owns approximately 5.9% of the outstanding Shares, (ii) Velan Horizon beneficially owns less than 1% of the outstanding Shares, (iii) Velan Horizon GP may be deemed to beneficially own less than 1% of the outstanding Shares, (iv) Velan GP may be deemed to beneficially own approximately 5.9% of the outstanding Shares, (v) Velan Capital may be deemed to beneficially own approximately 5.9% of the outstanding Shares, (vi) Velan IM GP may be deemed to beneficially own approximately 5.9% of the outstanding Shares, (vii) Mr. Morgan may be deemed to beneficially own approximately 5.9% of the outstanding Shares and (viii) Mr. Venkataraman may be deemed to beneficially own approximately 5.9% of the outstanding Shares.

(c)Number of shares as to which such person has:
(i)Sole power to vote or to direct the vote:

See Cover Pages Items 5-9.

(ii)Shared power to vote or to direct the vote:

See Cover Pages Items 5-9.

(iii)Sole power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

(iv)Shared power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

Item 5.Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8.Identification and Classification of Members of the Group.

See Exhibit 99.1.

Item 9.Notice of Dissolution of Group.

Not Applicable.

13

CUSIP No. 74365U107

Item 10.Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

14

CUSIP No. 74365U107

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: December 17, 2024

  Velan Capital Master Fund LP
   
  By: Velan Capital Holdings LLC
General Partner
   
  By:

/s/ Adam Morgan

    Name: Adam Morgan
    Title: Managing Member

 

 

  Velan Horizon Fund LP
   
  By: Velan Horizon GP LLC
General Partner
   
  By:

/s/ Adam Morgan

    Name: Adam Morgan
    Title: Managing Member

 

 

  Velan Horizon GP LLC
     
  By:

/s/ Adam Morgan

    Name: Adam Morgan
    Title: Managing Member

 

 

  Velan Capital Holdings LLC
     
  By:

/s/ Adam Morgan

    Name: Adam Morgan
    Title: Managing Member

 

 

  Velan Capital Investment Management LP
   
  By: Velan Capital Management LLC
General Partner
   
  By:

/s/ Adam Morgan

    Name: Adam Morgan
    Title: Managing Member

  

15

CUSIP No. 74365U107

  Velan Capital Management LLC
   
  By:

/s/ Adam Morgan

    Name: Adam Morgan
    Title: Managing Member

 

 

 

/s/ Adam Morgan

  Adam Morgan

 

 

 

/s/ Balaji Venkataraman

  Balaji Venkataraman

 

16
Get the next $TARA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TARA

DatePrice TargetRatingAnalyst
3/14/2025Overweight
Cantor Fitzgerald
7/10/2023$22.00Buy
Guggenheim
11/8/2021$32.00 → $34.00Outperform
Oppenheimer
More analyst ratings

$TARA
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

    NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that two presentations and a panel discussion highlighting the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured at the upcoming American Urological Association (AUA) 2025 Annual Meeting taking place from April 26, 2025 to April 29, 2025 in Las Vegas.  A copy of the abstract for the ADVANCED-2 interim analysis is now available on the AUA website. Updated safety and efficacy data, including data from

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

    Data to be featured during oral presentation at the American Society for Parenteral and Enteral Nutrition 2025 Nutrition Science & Practice ConferenceDosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025 NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS), will be featured

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

    Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announcement of initial data from 12-month evaluable patients expected by mid-2025Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025On track to provide an interim update from the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients by the end of 1H 2025Cash, cash equivalents and investments of $170 million as of December 31, 2024, including gross proceeds from $100 million public offering in December 2024, expected to support planned operations into 2027 NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) --

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TARA
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TARA
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TARA
 SEC Filings

See more

$TARA
 Leadership Updates

Live Leadership Updates

See more

  • Protara Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Business Overview

    - Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position of $130.7M as of December 31, 2021 Expected to Fund Operations into Mid-2024 - NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update. "Following a productive 2021, we are well poised to advance our pipeline in 2022, in particular, we are excited to have commenced our Phase 1 study of TARA-002 in non-muscle invasive b

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

    NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, and where he maintains a faculty appointment. Dr. Bandari joined Protara in April 2020 as Vice President, Head of Clinical Development, and most recently was Interim Chief Medical Officer. "We are thr

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview

    - Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to be Completed by Year-End - - Company Plans to Engage with FDA to Determine Clinical Trial Design for TARA-002 in Lymphatic Malformations - - Strong Cash, Cash Equivalents, and Investments Position of $145M as of June 30, 2021 - NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced financial results for the se

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TARA
 Financials

Live finance-specific insights

See more

  • Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

    TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month landmark complete response rate and 80% complete response rate at any time observed in BCG-Unresponsive patients64% six-month landmark complete response rate and 67% complete response rate at any time observed in BCG-Naïve patients80% reinduction salvage rate and compelling durability observed with 100% of patients maintaining a complete response from three months to six months across BCG exposuresFavorable safety and tolerability profile with no Grade 2 or greater treatment-related adverse eventsCompany to host conference call and webcast today at

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024

    NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, December 5, 2024, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology on December 5, 2024, at 1:15 p.m. CT. The live call can be accessed by registering as a participant here. Upo

    $TARA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$TARA
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more